相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wyndham H. Wilson et al.
CANCER CELL (2021)
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2
Wenjun Wu et al.
BLOOD ADVANCES (2021)
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
Pin Lu et al.
BLOOD CANCER JOURNAL (2021)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Binu K. Sasi et al.
LEUKEMIA (2019)
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
Grzegorz S. wakowski et al.
BLOOD CANCER JOURNAL (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
Jimmy Lee et al.
BLOOD ADVANCES (2018)
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B
Mei Ming et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma
Kai Ding et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
Ailin Guo et al.
ONCOTARGET (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
Ailin Guo et al.
ONCOTARGET (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
Shuang Q. Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
Jiao Ma et al.
ONCOTARGET (2015)
Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
S. Cheng et al.
LEUKEMIA (2015)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy
T. E. Witzig et al.
LEUKEMIA (2014)
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
K. H. Shain et al.
ONCOGENE (2014)
The regulatory roles of phosphatases in cancer
J. Stebbing et al.
ONCOGENE (2014)
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma
Daniela Capello et al.
HEMATOLOGICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Constitutive activation of STAT3 in Sezary syndrome is independent of SHP-1
R. C. T. McKenzie et al.
LEUKEMIA (2012)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti et al.
BLOOD (2005)
SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma:: implications for epigenetic activation of the Jak/STAT pathway
CS Chim et al.
LEUKEMIA (2004)
Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation
M Koyama et al.
LABORATORY INVESTIGATION (2003)
Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: Combination analysis with cDNA expression array and tissue microarray
T Oka et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction
I Tamir et al.
CURRENT OPINION IN IMMUNOLOGY (2000)
分享论文
